Technical Report No. 3-87
Monoclonal antibodies KL-3 and KL-6 against human pulmonary adenocarcinoma: 2. Detection of soluble antigen in sera and pleural effusion
Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido MEditor’s note: A publication based on this report was published in Jpn J Clin Oncol 18:203-16, 1988.
Summary
Two monoclonal antibodies, KL-3 and KL-6, were produced by immunization with the human pulmonary adenocarcinoma cell line VMRC-LCR. Both antigen determinants recognized by KL-3 and KL-6 antibodies appear to be carbohydrate in nature. The molecular weights of both soluble antigens in pleural effusions were found to be greater than 1,000 K. While elevated levels of KL-3 antigen in sera were found only in those patients with gastric and pancreatic cancer, KL-6 antigen levels were above normal in sera of patients with lung cancer, especially advanced adenocarcinoma, and pancreatic cancer and breast cancer. In benign diseases of the lung and other organs, only sera from patients with active pulmonary tuberculosis who had extensive lung damage had notably elevated KL-6 antigen levels. Serum levels of KL-6 antigen also bore no relationship to those of CEA, CA19-9, CRP, and to BSR. In pleural effusions, the prevalence of lung adenocarcinoma cases with elevated levels of KL-3 and KL-6 antigens was 76% and 82%, respectively, whereas nonmalignant pleural effusions, including those from tuberculosis and cholesterin pleuritis, were mostly shown to have normal levels of these antigens.
These monoclonal antibodies define soluble antigens that, in combination with other tumor markers, may be clinically useful for tumor diagnosis and monitoring tumor progression.
Two monoclonal antibodies, KL-3 and KL-6, were produced by immunization with the human pulmonary adenocarcinoma cell line VMRC-LCR. Both antigen determinants recognized by KL-3 and KL-6 antibodies appear to be carbohydrate in nature. The molecular weights of both soluble antigens in pleural effusions were found to be greater than 1,000 K. While elevated levels of KL-3 antigen in sera were found only in those patients with gastric and pancreatic cancer, KL-6 antigen levels were above normal in sera of patients with lung cancer, especially advanced adenocarcinoma, and pancreatic cancer and breast cancer. In benign diseases of the lung and other organs, only sera from patients with active pulmonary tuberculosis who had extensive lung damage had notably elevated KL-6 antigen levels. Serum levels of KL-6 antigen also bore no relationship to those of CEA, CA19-9, CRP, and to BSR. In pleural effusions, the prevalence of lung adenocarcinoma cases with elevated levels of KL-3 and KL-6 antigens was 76% and 82%, respectively, whereas nonmalignant pleural effusions, including those from tuberculosis and cholesterin pleuritis, were mostly shown to have normal levels of these antigens.
These monoclonal antibodies define soluble antigens that, in combination with other tumor markers, may be clinically useful for tumor diagnosis and monitoring tumor progression.